Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 13,600 shares, a decline of 46.5% from the January 15th total of 25,400 shares. Based on an average daily volume of 56,100 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price objective on shares of Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Monday, January 13th.

Barinthus Biotherapeutics Stock Up 0.5 %

Shares of NASDAQ BRNS traded up $0.01 during trading on Thursday, reaching $1.07. 26,033 shares of the stock were exchanged, compared to its average volume of 45,263. The business’s 50-day moving average price is $1.04 and its 200 day moving average price is $1.18. Barinthus Biotherapeutics has a twelve month low of $0.80 and a twelve month high of $4.16. The company has a market capitalization of $42.84 million, a price-to-earnings ratio of -0.71 and a beta of -0.82.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.